| Dr Karen Ellen Minzer-conzetti, MD | |
|
301 Ne Knott St, Portland, OR 97212-3014 | |
| (503) 253-3910 | |
| (503) 253-4297 |
| Full Name | Dr Karen Ellen Minzer-conzetti |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 17 Years |
| Location | 301 Ne Knott St, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508010372 | NPI | - | NPPES |
| 500632829 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 17828 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Portland Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
When a woman is in labour, the appropriate time to give an epidural during childbirth is when she asks for it, a new study suggests.
It's not a magic trick and it's not sleight of hand - scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects.
› Verified 3 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
When a woman is in labour, the appropriate time to give an epidural during childbirth is when she asks for it, a new study suggests.
It's not a magic trick and it's not sleight of hand - scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Karen Ellen Minzer-conzetti, MD 301 Ne Knott St, Portland, OR 97212-3014 Ph: (503) 253-3910 | Dr Karen Ellen Minzer-conzetti, MD 301 Ne Knott St, Portland, OR 97212-3014 Ph: (503) 253-3910 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
When a woman is in labour, the appropriate time to give an epidural during childbirth is when she asks for it, a new study suggests.
It's not a magic trick and it's not sleight of hand - scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects.
› Verified 3 days ago
Dr. Alison Marie Small, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 3303 Sw Bond Ave, Portland, OR 97239 Phone: 503-418-3376 | |
Milie Fang, DO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3303 S Bond Ave Dept, Portland, OR 97239 Phone: 503-494-1375 | |
Bert G Tavelli, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2525 Nw Lovejoy St Ste 400, Portland, OR 97210 Phone: 503-223-1933 Fax: 503-223-1947 | |
Natasha Fewkes Carter, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4914 Sw 1st Ave, Portland, OR 97239 Phone: 310-701-8274 | |
Dr. Samuel Fritz Bremmer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8211 | |
Oluwadamilare Olalekan Ajayi, MD Dermatology Medicare: Medicare Enrolled Practice Location: 3303 S Bond Ave, Portland, OR 97239 Phone: 503-418-3376 Fax: 503-494-6968 | |
Diane Romayne Baker, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 9495 Sw Locust St Ste A&e, Portland, OR 97223 Phone: 503-471-0500 Fax: 503-471-0504 |